Dimerix bags Advanz payment in kidney disease deal

6 November 2023
dimerix-large-1

Australian inflammatory diseases specialist Dimerix (ASX: DXB) has received an initial payment of 6.5 million euros ($7 million) in line with the recently-announced license agreement with Advanz Pharma.

Under the agreement, Advanz has been granted exclusive rights to commercialize DMX-200 for the kidney disease focal segmental glomerulosclerosis (FSGS) in the European Economic Area, the UK, Switzerland, Canada, Australia, and New Zealand.

Dimerix has retained all commercial rights to DMX-200 outside the Advanz territories, as well as all other indications globally.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology